NCT04963608Unknown不适用
Real World Study of Inetetamab HER2 Positive Advanced Breast Cancer
Zhiyong Yu0 个研究点目标入组 100 人开始时间: 2021年7月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 100
- 主要终点
- Progression Free Survival(PFS)
研究概览
简要总结
This non-Interventional study will describe and analyze the clinical use of Inetetamab in clinical practice in the treatment of HER2 positive advanced breast cancer in the real world.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients with stage IV breast cancer
- •Patients with HER2 positive status
- •Patients that received Inetetamab
- •Patients that began Inetetamab therapy prior to June 30, 2021.
排除标准
- •Patients treated with an investigational anticancer agent Inetetamab
研究组 & 干预措施
non-interventional study
Her2 positive ABC patients who have received Inetetamab in the metastatic setting.
干预措施: Inetetamab (Drug)
结局指标
主要结局
Progression Free Survival(PFS)
时间窗: 12 months
Incidences of adverse events and toxicities
时间窗: 12 months
次要结局
未报告次要终点
研究者
Zhiyong Yu
Chief of breast department
Shandong Cancer Hospital and Institute
相似试验
尚未招募
不适用
A Real-world Study of Inetetamab for First-line Treatment of MBCReal-world StudyBreast CancerNCT05980208Hunan Cancer Hospital150
尚未招募
3 期
Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM PathwayBreast CancerNCT04736589Peking Union Medical College270
招募中
不适用
Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast CancerBreast NeoplasmsNCT05764941The First Affiliated Hospital with Nanjing Medical University100
招募中
不适用
A Real-world Efficacy and Safety Study of Amlotinib for HER2-negative Advanced Breast CancerBreast CancerNCT06340165The First Hospital of Jilin University153
招募中
不适用
Real-world Study of Trastuzumab Deruxtecan in Patients With Unresectable or Metastatic HER2-low Breast CancerBreast CancerNCT06727227AstraZeneca138